CME: Glaucoma: best practices and the emerging treatment landscape
ACCREDITATION EXPIRED: February 11, 2024
Activity Description / Statement of Need:
In this online, self-learning activity:
Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects approximately 64 million people worldwide.The prevalence of glaucoma is increasing, and more than 100 million people will have glaucoma by 2040. Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years, thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.
Target Audience:
The following healthcare professionals: ophthalmologists; physician assistants, nurse practitioners, and any other healthcare professionals with an interest in or who clinically encounter patients with glaucoma.
This program is supported by an educational grant from Santen.
Learners may participate in this activity free of charge.
Release Date: February 11, 2022 -- Expiration Date: February 11, 2024
Faculty: Jiun Do, MD, PhD
Agenda
|
Faculty introduction, disclosures |
|
Glaucoma and Ocular Hypertension Overview · Epidemiology · Clinical presentation · Diagnosis, IOP measurement, and monitoring |
|
Medical Management of Glaucoma · 2021 AAO guidelines o Treatment goals o IOP targets o Choosing therapy o Follow up and progression · Medical management o Prostaglandin analogs o Rho kinase inhibitors o Carbonic anhydrase inhibitors o Beta antagonists and blockers o Alpha agonists o Hyperosmotic agents o Novel formulations and emerging therapies · Patient case(s) |
|
Summary, best practice recap, conclusion |
Learning Objectives
By the end of the session the participant will be able to:
- Describe optimal intraocular pressure targets for patients with glaucoma
- Identify first-line pharmacotherapies for lowering intraocular pressure
- Compare available and emerging first and later line pharmacotherapies for the management of glaucoma
- Apply current guideline recommendations to patient cases, including the incorporation of novel pharmacotherapeutic agents and engagement in patient education
Accreditation
ACCME Activity #201837457
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Jiun Lap Do, MD, PhD, University of California San Diego, discloses that he has received financial compensation as a consultant and/or investigator for Nicox and VoxelCloud.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Santen
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Glaucoma: Updates from the AAO 2019 Annual Meeting
Glaucoma: Optimizing pharmacotherapeutic management strategies
Dry Eye Disease: Therapeutic Updates and Optimizing Treatment